Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy
NCT00346268
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- The patient's ASA physical status is 1 or 2 and he has a low risk (i.e.,<10%) of developing an acute coronary event within the next 10 years according to the PROCAM risk assessment calculator.
- The patient is scheduled to undergo routine radical prostatectomy performed under a standardized regimen of general anesthesia, and is expected to experience moderate to severe postsurgical pain in the absence of postoperative analgesia.
- The patient has a history of uncontrolled chronic disease or a concurrent clinically
significant illness or medical condition such as a diagnosed chronic pain condition,
which, in the Investigator's opinion, would contraindicate study participation or
confound interpretation of the results
- The patient has a history or current presence of congestive heart failure (NYHA
II-IV), established ischaemic heart disease, peripheral arterial disease and / or
cerebrovascular disease.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Birmingham, Alabama
- Florence, Alabama
- Mobile, Alabama
- Montgomery, Alabama
- Montgomery, Alabama
- Sheffield, Alabama
- Peoria, Arizona
- Phoenix, Arizona
- Little Rock, Arkansas
- Bakersfield, California
- Glendale, California
- Laguna Hills, California
- Los Angeles, California
- Pasadena, California
- Santa Barbara, California
- Vista, California
- Aurora, Colorado
- Englewood, Colorado
- Steamboat Springs, Colorado
- Hartford, Connecticut
- Inverness, Florida
- Lauderdale Lakes, Florida
- Pensacola, Florida
- Tampa, Florida
- Decatur, Georgia
- Mooresville, Indiana
- Kansas City, Kansas
- Merriam, Kansas
- New Orleans, Louisiana
- Great Falls, Montana
- Albany, New York
- Staten Island, New York
- Columbus, Ohio
- Altoona, Pennsylvania
- Altoona, Pennsylvania
- Johnstown, Pennsylvania
- Johnstown, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Somerset, Pennsylvania
- State College, Pennsylvania
- Hendersonville, Tennessee
- San Antonio, Texas
- San Antonio, Texas
- Temple, Texas
- Sheffield, Alabama
- Phoenix, Arizona
- San Clemente, California
- Fort Pierce, Florida
- Louisville, Kentucky
- Raleigh, North Carolina
- State College, Pennsylvania
- Austin, Texas
- Shenyang, Liaoning
- Beijing,
- Beijing,
- Beijing,
- Shanghai,
- Shanghai,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy | |||
Official Title ICMJE | Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy | |||
Brief Summary | The primary objective of this study is to demonstrate the opioid-sparing efficacy of parecoxib 40 mg intravenously given as a loading dose followed by 20 mg intravenously in the 24 hours after the end of surgery. | |||
Detailed Description | The study was terminated due to lack of recruitment due to competing alternative operation methods on 13September 2010. The decision to terminate the trial was not based on any safety concerns. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Pain, Postoperative | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Dirkmann D, Groeben H, Farhan H, Stahl DL, Eikermann M. Effects of parecoxib on analgesia benefit and blood loss following open prostatectomy: a multicentre randomized trial. BMC Anesthesiol. 2015 Mar 9;15:31. doi: 10.1186/s12871-015-0015-y. eCollection 2015. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 105 | |||
Original Enrollment ICMJE | 152 | |||
Actual Study Completion Date ICMJE | September 2010 | |||
Actual Primary Completion Date | September 2010 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Germany | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00346268 | |||
Other Study ID Numbers ICMJE | A3481066 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |